Targeting antitumor CD4 helper T cells with universal tumor-reactive helper peptides derived from telomerase for cancer vaccine

References

• Vesely MD, Kershaw MH, Schreiber RD, Smyth MJ. Natural innate and adaptive immunity to cancer. Annu Rev Immunol 2011; 29:235 - 71; http://dx.doi.org/10.1146/annurev-immunol-031210-101324; PMID: 21219185
   PubMed Web of Science ®Google Scholar
• Kennedy R, Celis E. Multiple roles for CD4+ T cells in anti-tumor immune responses. Immunol Rev 2008; 222:129 - 44; http://dx.doi.org/10.1111/j.1600-065X.2008.00616.x; PMID: 18363998
   PubMed Web of Science ®Google Scholar
• Pardoll DM, Topalian SL. The role of CD4+ T cell responses in antitumor immunity. Curr Opin Immunol 1998; 10:588 - 94; http://dx.doi.org/10.1016/S0952-7915(98)80228-8; PMID: 9794842
   PubMed Web of Science ®Google Scholar
• Fayolle C, Deriaud E, Leclerc C. In vivo induction of cytotoxic T cell response by a free synthetic peptide requires CD4+ T cell help. J Immunol 1991; 147:4069 - 73; PMID: 1684372
   PubMed Web of Science ®Google Scholar
• Hunder NN, Wallen H, Cao J, Hendricks DW, Reilly JZ, Rodmyre R, et al. Treatment of metastatic melanoma with autologous CD4+ T cells against NY-ESO-1. N Engl J Med 2008; 358:2698 - 703; http://dx.doi.org/10.1056/NEJMoa0800251; PMID: 18565862
   PubMed Web of Science ®Google Scholar
• Bennett SR, Carbone FR, Karamalis F, Flavell RA, Miller JF, Heath WR. Help for cytotoxic-T-cell responses is mediated by CD40 signalling. Nature 1998; 393:478 - 80; http://dx.doi.org/10.1038/30996; PMID: 9624004
   PubMed Web of Science ®Google Scholar
• Smith CM, Wilson NS, Waithman J, Villadangos JA, Carbone FR, Heath WR, et al. Cognate CD4(+) T cell licensing of dendritic cells in CD8(+) T cell immunity. Nat Immunol 2004; 5:1143 - 8; http://dx.doi.org/10.1038/ni1129; PMID: 15475958
   PubMed Web of Science ®Google Scholar
• Fehniger TA, Cooper MA, Nuovo GJ, Cella M, Facchetti F, Colonna M, et al. CD56bright natural killer cells are present in human lymph nodes and are activated by T cell-derived IL-2: a potential new link between adaptive and innate immunity. Blood 2003; 101:3052 - 7; http://dx.doi.org/10.1182/blood-2002-09-2876; PMID: 12480696
   PubMed Web of Science ®Google Scholar
• Qin Z, Blankenstein T. CD4+ T cell--mediated tumor rejection involves inhibition of angiogenesis that is dependent on IFN gamma receptor expression by nonhematopoietic cells. Immunity 2000; 12:677 - 86; http://dx.doi.org/10.1016/S1074-7613(00)80218-6; PMID: 10894167
   PubMed Web of Science ®Google Scholar
• Rakhra K, Bachireddy P, Zabuawala T, Zeiser R, Xu L, Kopelman A, et al. CD4(+) T cells contribute to the remodeling of the microenvironment required for sustained tumor regression upon oncogene inactivation. Cancer Cell 2010; 18:485 - 98; http://dx.doi.org/10.1016/j.ccr.2010.10.002; PMID: 21035406
   PubMed Web of Science ®Google Scholar
• Fridman WH, Pagès F, Sautès-Fridman C, Galon J. The immune contexture in human tumours: impact on clinical outcome. Nat Rev Cancer 2012; 12:298 - 306; http://dx.doi.org/10.1038/nrc3245; PMID: 22419253
   PubMed Web of Science ®Google Scholar
• Ladoire S, Arnould L, Mignot G, Apetoh L, Rébé C, Martin F, et al. T-bet expression in intratumoral lymphoid structures after neoadjuvant trastuzumab plus docetaxel for HER2-overexpressing breast carcinoma predicts survival. Br J Cancer 2011; 105:366 - 71; http://dx.doi.org/10.1038/bjc.2011.261; PMID: 21750556
   PubMed Web of Science ®Google Scholar
• Rosenberg SA, Yang JC, Restifo NP. Cancer immunotherapy: moving beyond current vaccines. Nat Med 2004; 10:909 - 15; http://dx.doi.org/10.1038/nm1100; PMID: 15340416
   PubMed Web of Science ®Google Scholar
• Kobayashi H, Celis E. Peptide epitope identification for tumor-reactive CD4 T cells. Curr Opin Immunol 2008; 20:221 - 7; http://dx.doi.org/10.1016/j.coi.2008.04.011; PMID: 18499419
   PubMed Web of Science ®Google Scholar
• Knutson KL, Disis ML. Tumor antigen-specific T helper cells in cancer immunity and immunotherapy. Cancer Immunol Immunother 2005; 54:721 - 8; http://dx.doi.org/10.1007/s00262-004-0653-2; PMID: 16010587
   PubMed Web of Science ®Google Scholar
• Zhu J, Paul WE. CD4 T cells: fates, functions, and faults. Blood 2008; 112:1557 - 69; http://dx.doi.org/10.1182/blood-2008-05-078154; PMID: 18725574
   PubMed Web of Science ®Google Scholar
• De Monte L, Reni M, Tassi E, Clavenna D, Papa I, Recalde H, et al. Intratumor T helper type 2 cell infiltrate correlates with cancer-associated fibroblast thymic stromal lymphopoietin production and reduced survival in pancreatic cancer. J Exp Med 2011; 208:469 - 78; http://dx.doi.org/10.1084/jem.20101876; PMID: 21339327
   PubMed Web of Science ®Google Scholar
• Tosolini M, Kirilovsky A, Mlecnik B, Fredriksen T, Mauger S, Bindea G, et al. Clinical impact of different classes of infiltrating T cytotoxic and helper cells (Th1, th2, treg, th17) in patients with colorectal cancer. Cancer Res 2011; 71:1263 - 71; http://dx.doi.org/10.1158/0008-5472.CAN-10-2907; PMID: 21303976
   PubMed Web of Science ®Google Scholar
• Godet Y, Fabre E, Dosset M, Lamuraglia M, Levionnois E, Ravel P, et al. Analysis of spontaneous tumor-specific CD4 T-cell immunity in lung cancer using promiscuous HLA-DR telomerase-derived epitopes: potential synergistic effect with chemotherapy response. Clin Cancer Res 2012; 18:2943 - 53; http://dx.doi.org/10.1158/1078-0432.CCR-11-3185; PMID: 22407833
   PubMed Web of Science ®Google Scholar
• Martínez P, Blasco MA. Telomeric and extra-telomeric roles for telomerase and the telomere-binding proteins. Nat Rev Cancer 2011; 11:161 - 76; http://dx.doi.org/10.1038/nrc3025; PMID: 21346783
   PubMed Web of Science ®Google Scholar
• Harley CB. Telomerase and cancer therapeutics. Nat Rev Cancer 2008; 8:167 - 79; http://dx.doi.org/10.1038/nrc2275; PMID: 18256617
   PubMed Web of Science ®Google Scholar
• Dosset M, Godet Y, Vauchy C, Beziaud L, Lone YC, Sedlik C, et al. Universal cancer peptide-based therapeutic vaccine breaks tolerance against telomerase and eradicates established tumor. Clin Cancer Res 2012; 18:6284 - 95; http://dx.doi.org/10.1158/1078-0432.CCR-12-0896; PMID: 23032748
   PubMed Web of Science ®Google Scholar
• Ridge JP, Di Rosa F, Matzinger P. A conditioned dendritic cell can be a temporal bridge between a CD4+ T-helper and a T-killer cell. Nature 1998; 393:474 - 8; http://dx.doi.org/10.1038/30989; PMID: 9624003
   PubMed Web of Science ®Google Scholar
• Adotévi O, Mollier K, Neuveut C, Dosset M, Ravel P, Fridman WH, et al. Targeting human telomerase reverse transcriptase with recombinant lentivector is highly effective to stimulate antitumor CD8 T-cell immunity in vivo. Blood 2010; 115:3025 - 32; http://dx.doi.org/10.1182/blood-2009-11-253641; PMID: 20130242
   PubMed Web of Science ®Google Scholar
• Hernandez J, Garcia-Pons F, Lone YC, Firat H, Schmidt JD, Langlade-Demoyen P, et al. Identification of a human telomerase reverse transcriptase peptide of low affinity for HLA A2.1 that induces cytotoxic T lymphocytes and mediates lysis of tumor cells. Proc Natl Acad Sci U S A 2002; 99:12275 - 80; http://dx.doi.org/10.1073/pnas.182418399; PMID: 12218171
   PubMed Web of Science ®Google Scholar
• Scardino A, Gross DA, Alves P, Schultze JL, Graff-Dubois S, Faure O, et al. HER-2/neu and hTERT cryptic epitopes as novel targets for broad spectrum tumor immunotherapy. J Immunol 2002; 168:5900 - 6; PMID: 12023395
   PubMed Web of Science ®Google Scholar
• del Guercio MF, Alexander J, Kubo RT, Arrhenius T, Maewal A, Appella E, et al. Potent immunogenic short linear peptide constructs composed of B cell epitopes and Pan DR T helper epitopes (PADRE) for antibody responses in vivo. Vaccine 1997; 15:441 - 8; http://dx.doi.org/10.1016/S0264-410X(97)00186-2; PMID: 9141216
   PubMed Web of Science ®Google Scholar
• Helling F, Zhang S, Shang A, Adluri S, Calves M, Koganty R, et al. GM2-KLH conjugate vaccine: increased immunogenicity in melanoma patients after administration with immunological adjuvant QS-21. Cancer Res 1995; 55:2783 - 8; PMID: 7796403
   PubMed Web of Science ®Google Scholar
• Scheibenbogen C, Schadendorf D, Bechrakis NE, Nagorsen D, Hofmann U, Servetopoulou F, et al. Effects of granulocyte-macrophage colony-stimulating factor and foreign helper protein as immunologic adjuvants on the T-cell response to vaccination with tyrosinase peptides. Int J Cancer 2003; 104:188 - 94; http://dx.doi.org/10.1002/ijc.10961; PMID: 12569574
   PubMed Web of Science ®Google Scholar
• Valmori D, Pessi A, Bianchi E, Corradin G. Use of human universally antigenic tetanus toxin T cell epitopes as carriers for human vaccination. J Immunol 1992; 149:717 - 21; PMID: 1378079
   PubMed Web of Science ®Google Scholar
• Slingluff CL Jr., Petroni GR, Chianese-Bullock KA, Smolkin ME, Ross MI, Haas NB, et al. Randomized multicenter trial of the effects of melanoma-associated helper peptides and cyclophosphamide on the immunogenicity of a multipeptide melanoma vaccine. J Clin Oncol 2011; 29:2924 - 32; http://dx.doi.org/10.1200/JCO.2010.33.8053; PMID: 21690475
   PubMed Web of Science ®Google Scholar
• Wong SB, Bos R, Sherman LA. Tumor-specific CD4+ T cells render the tumor environment permissive for infiltration by low-avidity CD8+ T cells. J Immunol 2008; 180:3122 - 31; PMID: 18292535
   PubMed Web of Science ®Google Scholar
• Marzo AL, Kinnear BF, Lake RA, Frelinger JJ, Collins EJ, Robinson BW, et al. Tumor-specific CD4+ T cells have a major “post-licensing” role in CTL mediated anti-tumor immunity. J Immunol 2000; 165:6047 - 55; PMID: 11086036
   PubMed Web of Science ®Google Scholar
• Bos R, Sherman LA. CD4+ T-cell help in the tumor milieu is required for recruitment and cytolytic function of CD8+ T lymphocytes. Cancer Res 2010; 70:8368 - 77; http://dx.doi.org/10.1158/0008-5472.CAN-10-1322; PMID: 20940398
   PubMed Web of Science ®Google Scholar
• Gross DA, Graff-Dubois S, Opolon P, Cornet S, Alves P, Bennaceur-Griscelli A, et al. High vaccination efficiency of low-affinity epitopes in antitumor immunotherapy. J Clin Invest 2004; 113:425 - 33; PMID: 14755339
   PubMed Web of Science ®Google Scholar
• Nakanishi Y, Lu B, Gerard C, Iwasaki A. CD8(+) T lymphocyte mobilization to virus-infected tissue requires CD4(+) T-cell help. Nature 2009; 462:510 - 3; http://dx.doi.org/10.1038/nature08511; PMID: 19898495
   PubMed Web of Science ®Google Scholar
• Zitvogel L, Kepp O, Kroemer G. Immune parameters affecting the efficacy of chemotherapeutic regimens. Nat Rev Clin Oncol 2011; 8:151 - 60; http://dx.doi.org/10.1038/nrclinonc.2010.223; PMID: 21364688
   PubMed Web of Science ®Google Scholar
• Galluzzi L, Senovilla L, Zitvogel L, Kroemer G. The secret ally: immunostimulation by anticancer drugs. Nat Rev Drug Discov 2012; 11:215 - 33; http://dx.doi.org/10.1038/nrd3626; PMID: 22301798
   PubMed Web of Science ®Google Scholar
• Godet Y, Dosset M, Borg C, Adotevi O. Is preexisting antitumor CD4 T cell response indispensable for the chemotherapy induced immune regression of cancer?. Oncoimmunology 2012; 1:1617 - 9; http://dx.doi.org/10.4161/onci.21513; PMID: 23264913
   PubMed Web of Science ®Google Scholar
• Ding ZC, Zhou G. Cytotoxic chemotherapy and CD4+ effector T cells: an emerging alliance for durable antitumor effects. Clin Dev Immunol 2012; 2012:890178; http://dx.doi.org/10.1155/2012/890178; PMID: 22400040
   PubMed Web of Science ®Google Scholar
• Terme M, Pernot S, Marcheteau E, Sandoval F, Benhamouda N, Colussi O, et al. VEGFA-VEGF Receptor pathway blockade inhibits tumor-induced regulatory T cell proliferation in colorectal cancer. Cancer Res 2013; 73:539 - 49; http://dx.doi.org/10.1158/0008-5472.CAN-12-2325; PMID: 23108136
   PubMed Web of Science ®Google Scholar
• Adotevi O, Pere H, Ravel P, Haicheur N, Badoual C, Merillon N, et al. A decrease of regulatory T cells correlates with overall survival after sunitinib-based antiangiogenic therapy in metastatic renal cancer patients. J Immunother 2010; 33:991 - 8; http://dx.doi.org/10.1097/CJI.0b013e3181f4c208; PMID: 20948437
   PubMed Web of Science ®Google Scholar